Exhibit 99.1 DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Preliminary Data from KOMET-007 – January 30, 2024
WELCOME AND INTRODUCTION Troy Wilson, Ph.D., J.D. – President & Chief Executive Officer, Kura Oncology
Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, tipifarnib and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, our expectations regarding the therapeutic and commercial potential of our product candidates, our expectations regarding our cash runway, and our expectations regarding our intended use of the net proceeds from the private placement that closed on January 26, 2024. The words “believe,” “may,” “should,” “will,” “estimate,” “promise,” “plan”, “continue,” “anticipate,” “intend,” “expect,” “potential” and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical trials may not be successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; our product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; we may not be able to obtain additional financing; risks associated with market conditions and the satisfaction of closing conditions related to the private placement; risks associated with our cash needs; and risks and uncertainties associated with our business and finances in general. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura’s management to predict all risk factors and uncertainties. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. This presentation also contains statistical and clinical data obtained from and prepared by third parties. The recipient is cautioned not to give undue weight to such disclosures. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. 3
Targeting Foundational Mutations has Transformed Deadly Hematologic Cancers into Chronic Diseases Acute Promyelocytic Leukemia Acute Promyelocytic Leukemia (APL) • APL arises from an abnormal fusion protein called PML/RARα, which is mechanistically similar to the menin-KMT2A complex in AML. • ATRA/ATO therapy is a combination treatment of all- trans retinoic acid (ATRA) and arsenic trioxide (ATO). • The mechanism of action of ATRA/ATO therapy is differentiation of promyelocytes, immature white blood cells. • ATRA/ATO combinations have fundamentally transformed the treatment of APL. ATRA/ATO combinations demonstrate curative potential with 89% overall survival at 10 Years Gurnari: APL in Children, A Model of Precision Medicine and Chemotherapy-Free Therapy: IJMS 2021 4
Targeting Foundational Mutations has Transformed Deadly Hematologic Cancers into Chronic Diseases Multiple Myeloma • Until the 2000’s, there were few treatment options for multiple myeloma, and the median survival was 2–3 years. • With the advent of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) in the 2000’s, the outcomes of patients are now significantly improving. • Many patients can now live with their disease > 10 years. • IMiDs have become a cornerstone of treatment for patients with multiple myeloma and are used in combinations at all stages of disease. IMiD combinations increased 5yr OS from 35% to > 65%; class generated ~$15B in revenues at peak Holstein and McCarthy, Drugs (2017) 77(5), 505-520 Bird, S. and Pawlyn, C. Blood (2023) 142(2): 131-140 5
ZIFTOMENIB OPPORTUNITY AND INTRODUCTION TO KOMET-007 INVESTIGATORS Stephen Dale, M.D. – Chief Medical Officer, Kura Oncology
Ziftomenib Demonstrates Potential to Become a Cornerstone of AML Therapy Targets foundational mutations at the core of up to 50% of AML cases • Compelling clinical data support frontline opportunity • Good tolerability profile, enabling continuous administration in combination with SOC • Combinations appear to mitigate the risk of differentiation syndrome • No observed or predicted drug-drug interactions • Encouraging preliminary evidence of clinical activity • Strong investigator enthusiasm as evidenced by rapid enrollment across studies • First 20 patients enrolled in KOMET-007 combination trial in less than four months • KOMET-001 monotherapy registrational trial expected to complete enrollment by mid-2024 7
KOMET-007 Investigators Amir Fathi, M.D. Amer Zeidan, MBBS • Program Director, Center for Leukemia, • Interim Chief, Division of Hematologic Massachusetts General Hospital Cancer Center Malignancies, Director of Hematology Early Therapeutics Research, Yale Cancer Center • Associate Professor of Medicine, Harvard Medical School • Associate Professor of Medicine (Hematology), Yale University 8
ZIFTOMENIB AS MONOTHERAPY / OPPORTUNITY IN COMBINATION Amir Fathi, M.D. – Massachusetts General Hospital
KOMET-001 Phase 1/2 Study of Ziftomenib in Relapsed/Refractory AML Phase 1a Phase 1b Phase 2 Phase 1b Dose Escalation Expansion Registration-Enabling Validation Cohorts (Ongoing) Completed Completed Completed Ongoing Expansion of 600 mg QD Cohort 1: 200 mg QD 50 mg 100 mg 1000 mg 600 mg QD QD QD QD Cohort 2: 600 mg QD NPM1-m, KMT2A-r, Other NPM1-m NPM1-m NPM1-m or KMT2A-r OBJECTIVES • Safety and tolerability Continue enrollment of Phase • Primary endpoint: • Safety and tolerability • CR/CRh • Pharmacokinetics 1b validation cohort(s) • Pharmacokinetics • Early evidence of antitumor consistent with FDA’s Project • Clinical activity • Secondary endpoints: activity Optimus • Duration of CR/CRh • Safety and tolerability • Transfusion independence • Pharmacokinetics • CR/CRh MRD negativity • Adverse events • Clinical activity CR, complete remission; CRh, complete remission with partial hematological recovery; FDA, United States Food and Drug Administration; MRD, measurable residual disease; R/R, relapsed/refractory; RP2D, recommended phase 2 dose. 10 ~ ~
Dose-Proportional Increase in Ziftomenib Exposure Supports 600 mg Dose AUC = area under the curve 11
Ziftomenib Demonstrates Encouraging Safety Profile in Phase 1b • Differentiation syndrome (DS) appears manageable in NPM1-m monotherapy patients with mitigation strategy • 20% rate of mild to moderate DS • Rates of DS in KMT2A-r monotherapy patients were 38.5% at 200 mg and 37.5% at 600 mg; potential to mitigate in combination • DS is an on-target AE and represents evidence of clinical activity • No reports of drug-induced QTc prolongation • Maintained count recovery suggests no drug-induced myelosuppression Fathi et al. EHA 2023 #LB2713 (preliminary data as of April 12, 2023) 12
Ziftomenib has Highly Differentiated Monotherapy Activity Best Overall Response 600 mg Differentiated CR Rates vs. SOC in NPM1-m Phase 1a + 1b (n=20) 40% of NPM1 Heavily Pretreated Patients patients CR 7 (35.0) achieved a MEDIAN CR/CRh 7 (35.0) MUTATION CR % mDOR CR during PRIORS course of CRc 8 (40.0) NPM1m 8.2 mo* 35% study Ziftomenib 1 MRD negativity 4(50.0) FLT3m - 3 33% 600mg QD IDH 1/2 - 50% ORR 9 (45.0) Gilteritinib FLT3m 14.2% 14.8 mo 1 KMT2A-r Phase 1a + 1b (n=18) Enasidenib IDH2 19% 8.2 mo 2 CR/CRh 2 (11.1) Ivosidenib IDH1 25% 10.1 mo 2 CRc 3 (16.7) *Median DoR for CRc without censoring at HSCT MRD negativity 3 (100.0) Source: USPI’s ORR 3 (16.7) (preliminary data as of April 10, 2023) Ø High activity, durable responses and favorable profile suggest potential for ziftomenib to become a backbone therapy across the continuum of AML care 1 MRD was assessed for 6/8 CRc patients; 4 of those 6 patients (67%) tested were MRD negative 13 CRc includes CR, CRh, CRi, CRp; ORR includes CR, CRh, CRi, CRp, MLFS
Maximizing the Therapeutic Value of Menin Inhibitors Will Come Through Combinations Clinical Activity – Enhanced relative to SOC Pharmacoeconomic Benefit – Safety/Tolerability – Minimal Fewer requirements for monitoring additive toxicity over SOC and hospitalization Quality of Life – Fewer Drug-Drug Interactions – Minimal to none concomitant meds, less toxicity Resistance – Potential to address Synergistic MOA – Ideally, additive / innate and adaptive resistance to SOC synergistic to SOC MRD – Potential to achieve greater depth of response Holstein and McCarthy, Drugs 77(5), 505-520 (2017); 14 Bird, S. and Pawlyn, C. Blood (2023) 142(2): 131-140
PRELIMINARY COMBINATION DATA FROM KOMET-007 TRIAL Amer Zeidan, MBBS – Yale Cancer Center Disclosure: Honoraria or consultation fees provided by Kura Oncology
KOMET-007: Phase 1 Combination Trial of Ziftomenib in Patients with Newly Diagnosed or R/R AML Ziftomenib/cytarabine/daunorubicin (7+3) combination • Ziftomenib dosing will begin on Cycle 1 Day 8 and be administered continuously thereafter • Cytarabine will be administered on C1 Day 1-7; administration of an additional cycle based on C1 bone marrow biopsy results • Daunorubicin will be administered on C1 Day 1- 3; administration of an additional cycle based on C1 bone marrow biopsy results • Dose escalation conducted in patients with adverse risk* *Age > 60 years and/or treatment-related AML and/or adverse risk cytogenetics per ELN 16 DL = ziftomenib dose level; zifto = ziftomenib; 7+3 = cytarabine/daunorubicin; RP2D = recommended Phase 2 dose; 1L = first-line; IC = intensive chemotherapy
KOMET-007: Phase 1 Combination Trial of Ziftomenib in Patients with Newly Diagnosed or R/R AML Ziftomenib/venetoclax/azacitidine combination • Ziftomenib dosing will begin on Cycle 1 Day 8 and be administered continuously thereafter • Venetoclax will be administered per label in 28-day cycles with adjustments to cycle length based on C1 bone marrow biopsy results • Azacitidine will be administered per label on C1 Day 1-7 of each cycle with additional cycles based on bone marrow biopsy results DL = ziftomenib dose level; zifto = ziftomenib; ven = venetoclax; ven = venetoclax; RP2D = recommended Phase 2 dose; NIC = non-intensive chemotherapy; 17 1L = first-line; R/R = relapsed/refractory
KOMET-007: Patient Demographics and Disposition First 20 Patients Enrolled • Relapsed/refractory patients with NPM1-m or KMT2A-r AML in combination with venetoclax/azacitidine • Newly-diagnosed patients with adverse risk* NPM1-m or KMT2A-r AML in combination with cytarabine/daunorubicin (7+3) • 80% (16/20) of patients remain on trial as of January 11, 2024, including 100% of patients with NPM1-m AML Cohorts R/R NPM1-m 1L NPM1-m R/R KMT2A-r 1L KMT2A-r Ven/Aza 7+3 Ven/Aza 7+3 All Age, years (Median, range) 55.5 (23, 77) 55.0 (41, 77) 65.5 (43, 74) 52.5 (23, 71) 49.0 (49, 49) 13 (65) 4 (57) 2 (50) 6 (75) 1 (100) Female (n, %) Genetic Subtypes [n (%)] NPM1-m 11 (55) 7 (100) 4 (100) N/A N/A KMT2A-r 9 (45) N/A N/A 8 (100) 1 (100) ECOG PS [n (%)] 0 4 (20) 1 (14) 3 (75) 0 0 1 11 (55) 5 (71) 0 5 (63) 1 (100) 2 5 (25) 1 (14) 1 (25) 3 (38) 0 Prior Therapies (Median, Range) N/A 2 (1,12) 0 2 (1,6) 0 Prior Antineoplastic Therapy [n (%)] Stem Cell Transplant 7 (47) 4 (57) N/A 3 (38) N/A Hypomethylating Agent (HMA) 8 (53) 4 (57) N/A 4 (50) N/A Venetoclax 10 (67) 5 (71) N/A 5 (63) N/A Menin Inhibitors 6 (40) 2 (29) N/A 4 (50) N/A Preliminary data as of January 11, 2024 18 *Age > 60 years and/or treatment-related AML and/or adverse risk cytogenetics per European LeukemiaNet (ELN)
KOMET-007: Promising Safety and Tolerability Profile in Combination Combinations mitigate risk of differentiation syndrome (DS) Grade ≥ 3 TEAEs (≥ 10%) n (%) Grade ≥ 3 Ziftomenib-Related AEs (All) n (%) Patients with Grade ≥ 3 TEAEs 18 (90) Patients with Grade ≥ 3 Ziftomenib-Related AEs 6 (30) Platelet count decreased 6 (30) Platelet count decreased 3 (15) Febrile neutropenia 5 (25) Anemia 1 (5) White blood cell count decreased 4 (20) Febrile neutropenia 1 (5) Pneumonia 3 (15) Leukopenia 1 (5) Hypoxia 2 (10) Neutrophil count 1 (5) Neutrophil count decreased 2 (10) Thrombocytopenia 1 (5) Sepsis 2 (10) Thrombocytopenia 2 (10) • No DS events reported • No dose-limiting toxicities (DLTs) observed to date, including delayed hematologic count recovery • No QTc prolongation observed • TEAEs consistent with underlying disease and backbone therapies Preliminary data as of January 11, 2024 19 TEAEs = Treatment-emergent adverse events
100% CR rate with Ziftomenib and 7+3 in 1L Patients with Adverse-Risk AML* 1,2 • Anticipated CR/CRi rate with 7+3 in all-comer 1L adverse risk patients: 32-33% 1L Adverse-Risk Group CR Rate n=5 (n) Overall (NPM1-m + KMT2A-r) 100% (5) NPM1-m only (n=4) 100% (4) KMT2A-r only (n=1) 100% (1) • All patients treated in initial dose cohort (200 mg) in combination with 7+3 Preliminary data as of January 11, 2024 1 Lancet et al. Blood. 2014 May 22;123(21):3239-46. 2 Lin et al. Blood Adv. 2021 Mar 23;5(6):1719-1728. 20 *Age > 60 years and/or treatment-related AML and/or adverse risk cytogenetics per ELN
Ziftomenib + Ven/Aza with Pronounced Activity in Menin Inhibitor Naïve Patients 1 • ~35-45% CR/CRi is expected in ven-naïve relapsed/refractory patients 2 • Anticipated response rate in KMT2A-r relapsed/refractory AML <10% ORR • 53% ORR in mITT population (n=15, including six menin experienced patients) • 40% (6/15) of patients treated with ven/aza received prior treatment with a menin inhibitor Menin Inhibitor Naïve Group ORR CR/CRi Rate CR/CRh Rate n=9 (n) (n) (n) Overall (NPM1-m + KMT2A-r) 78% (7) 67% (6) 56% (5) NPM1-m (n=5) 100% (5) 80% (4) 60% (3) KMT2A-r (n=4) 50% (2) 50% (2) 50% (2) • All patients treated in initial dose cohort (200 mg) in combination with Ven/Aza • Enrollment in 400 mg dose cohort ongoing Preliminary data as of January 11, 2024 1 Stahl, M. et al., Blood Advances 5(5), 1552-1564 (2021) 2 Issa, Syndax ASH Investor Event (Dec. 2023) 21 ORR includes CR, CRh, CRi, MLFS
Ziftomenib + Ven/Aza Able to Drive Responses in Venetoclax Failures 1-4 • Expected response rates following ven/aza ~ 0-20% 4 • Anticipated response rate in KMT2A-r R/R AML < 10% ORR Venetoclax Experienced Group ORR CR/CRi Rate CR/CRh Rate n=10 (n) (n) (n) Overall (NPM1-m + KMT2A-r) 40% (4) 30% (3) 30% (3) NPM1-m (n=5) 60% (3) 40% (2) 40% (2) KMT2A-r (n=5) 20% (1) 20% (1) 20% (1) • All patients treated in initial dose cohort (200 mg) in combination with Ven/Aza • Enrollment in 400 mg dose cohort ongoing Preliminary data as of January 11, 2024 1 Zainaldin, C. et al., Lymphoma 63(13):3245-3248 (2022); 2 Chan, O. and Walker, A., Hematology 702-708 (2023); 3 Maiti A, et al., Haematologica. 2021; 106(3):894-898; 4 Issa, Syndax ASH Investor Event (Dec. 2023) 22 ORR includes CR, CRh, CRi, MLFS
Continued Use of Ziftomenib Following Successful Induction with 7+3 HSCT ziftomenib CR 7+3 WEEK 0 1 6 23 CYT Cohort: Frontline Ongoing post-HSCT DAU NPM1-m 7+3 ZIFTO Patient Characteristics • CR after one cycle of induction (week 5-6) Demographics 66-year-old female Mutational profile NPM1m, CBL, IDH2, NRAS, SRSF2 • Maintained ziftomenib from induction through consolidation until conditioning for transplant (~5 months) Baseline bone marrow blasts 77% • Post-transplant ziftomenib maintenance planned Best overall response CR Preliminary data as of January 11, 2024 23 ~ ~
Ziftomenib Combinations Are Effective in Treating Aggressive Disease ziftomenib Transition to R/R CR Relapse Cohort 7+3 WEEK 0 1 3 10 11 CYT Cohort: 1L KMT2A-r 7+3 DAU ZIFTO ziftomenib CRi HSCT Ven/Aza 6 WEEK 0 1 3 12 Cohort: R/R AZA KMT2A-r Ven/Aza VEN Ongoing post-HSCT ZIFTO Patient Characteristics Demographics 49-year-old female • Patient with highly aggressive disease including KRAS at 79% VAF • Initiated ziftomenib in 7+3 cohort: achieved CR post induction but Mutational profile KMT2Ar, KRAS relapsed post consolidation • Continued ziftomenib in Ven/Aza cohort: achieved remission and Baseline bone marrow blasts 10% (at relapse) proceeded to transplant Best overall response CR • MRD negative for KMT2Ar and KRAS at time of transplant Preliminary data as of January 11, 2024 24
Ziftomenib Eliminates Extramedullary Disease Unaffected by Prior Venetoclax in Heavily Pre-Treated Patient ziftomenib CRi CRh HSCT Ven/Aza 17 WEEK 0 1 4 8 10 AZA Cohort: R/R Ongoing post-HSCT VEN NPM1-m Ven/Aza ZIFTO C1D11: EMD “melted” within 2 days zifto start Patient Characteristics Prior lines of therapies Demographics 41-year-old female • 5+1 • 2nd induction w/ etoposide, cytarabine and midostaurin Mutational profile NPM1, FLT3-ITD, DNMT3A and CBL • Aza/Ven • MUD Allo SCT followed by gilteritinib maintenance Baseline bone marrow blasts Extramedullary disease (EMD) only • Decitabine and Ven • DLI and Ven Best overall response CRh • 2nd DLI Preliminary data as of January 11, 2024 25 ~ ~
CLINICAL DEVELOPMENT PLAN Mollie Leoni, M.D. – Executive Vice President, Clinical Development
Ziftomenib Clinical Development Path DEVELOPMENT APPROACH PLANNED STUDY STARTUP PHASE 1 REGISTRATION DIRECTED TRIAL NPM1-mutant acute myeloid leukemia (AML) MONOTHERAPY Non- NPM1-m/KMT2A-r AML (Relapsed/refractory) KMT2A-rearranged ALL COMBINATION WITH NPM1-mutant AML VENETOCLAX + AZACITIDINE KMT2A-rearranged AML (Relapsed/refractory, frontline) COMBINATION WITH NPM1-mutant AML CYTARABINE + DAUNORUBICIN (7+3) KMT2A-rearranged AML (Relapsed/refractory, frontline) COMBINATIONS WITH GILTERITINIB, NPM1-mutant AML FLAG-IDA, LDAC KMT2A-rearranged AML (Relapsed/refractory) NPM1-mutant AML Investigator / Company- POST-TRANSPLANT MAINTENANCE sponsored studies KMT2A-rearranged AML Pediatric AML & ALL COMBINATION WITH FLA Investigator-sponsored studies Pediatric ALL COMBINATION WITH BV-DAM 27
MARKET OPPORTUNITY AND UPCOMING MILESTONES Troy Wilson, Ph.D., J.D. – President & Chief Executive Officer, Kura Oncology
Ziftomenib Offers a Multi-Billion-Dollar Opportunity in AML and Beyond Potential to Transform Outcomes Across the Continuum of Care • Initial approval represents 30% of potential patients Relapsed / • KOMET-001 registration-directed study for FDA full approval Refractory • Significant opportunity in 1L AML and Maintenance Frontline / • Potential to drive > 50% revenue Maintenance • Safety, tolerability and clinical activity anticipated to be ideal for combinations with SOC and with maintenance indication • Compelling additional opportunities beyond AML offer multi- Other billion-dollar potential Indications • Early translational data supports potential in solid tumor and non-oncology indications 29
Upcoming Milestones for Ziftomenib in Acute Leukemia ESTIMATED TIME MILESTONE OF ACHIEVEMENT Dose first patients in KOMET-008 trial in combination with FLT3 inhibitor gilteritinib, Q1 2024 LDAC and FLAG-IDA Initiate post-transplant maintenance program Q1 2024 Expand ziftomenib development to acute lymphoblastic leukemia (ALL) Q1 2024 Complete enrollment of 85 patients in KOMET-001 registration-directed trial Mid-2024 Determine recommended Phase 2 dose in combination with ven/aza Mid-2024 Initiate dose validation/expansion in combination with ven/aza in 1L AML Mid-2024 Provide next KOMET-007 combination update 2024 • $570 million in pro forma cash* provides runway into 2027, enabling aggressive research, development and pre-commercial activities to maximize value of ziftomenib and other pipeline assets * Includes $424M in cash, cash equivalents and short-term investments as of 12/31/23 and estimated proceeds net of offering expenses of $146M from private placement closed on January 26, 2024 30
DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Preliminary Data from KOMET-007 – January 30, 2024
